Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 75 (3), 311-35

Natural Products as Sources of New Drugs Over the 30 Years From 1981 to 2010

Affiliations
Review

Natural Products as Sources of New Drugs Over the 30 Years From 1981 to 2010

David J Newman et al. J Nat Prod.

Abstract

This review is an updated and expanded version of the three prior reviews that were published in this journal in 1997, 2003, and 2007. In the case of all approved therapeutic agents, the time frame has been extended to cover the 30 years from January 1, 1981, to December 31, 2010, for all diseases worldwide, and from 1950 (earliest so far identified) to December 2010 for all approved antitumor drugs worldwide. We have continued to utilize our secondary subdivision of a "natural product mimic" or "NM" to join the original primary divisions and have added a new designation, "natural product botanical" or "NB", to cover those botanical "defined mixtures" that have now been recognized as drug entities by the FDA and similar organizations. From the data presented, the utility of natural products as sources of novel structures, but not necessarily the final drug entity, is still alive and well. Thus, in the area of cancer, over the time frame from around the 1940s to date, of the 175 small molecules, 131, or 74.8%, are other than "S" (synthetic), with 85, or 48.6%, actually being either natural products or directly derived therefrom. In other areas, the influence of natural product structures is quite marked, with, as expected from prior information, the anti-infective area being dependent on natural products and their structures. Although combinatorial chemistry techniques have succeeded as methods of optimizing structures and have been used very successfully in the optimization of many recently approved agents, we are able to identify only one de novo combinatorial compound approved as a drug in this 30-year time frame. We wish to draw the attention of readers to the rapidly evolving recognition that a significant number of natural product drugs/leads are actually produced by microbes and/or microbial interactions with the "host from whence it was isolated", and therefore we consider that this area of natural product research should be expanded significantly.

Figures

Figure 1
Figure 1. All New Approved Drugs; n = 1355
Figure 2
Figure 2. All New Approved Drugs by Source/Year
Figure 3
Figure 3. Source of Small Molecule Approved Drugs; n = 1073
Figure 4
Figure 4. Sources of Small Molecule NCEs by Source/Year
Figure 5
Figure 5. Percent N/NB/ND by Year, 1981 – 2010
Figure 6
Figure 6. Total Small Molecules by Year, 1981 – 2010
Figure 7
Figure 7. All Anticancer Drugs, 1981 – 2010
Figure 8
Figure 8. All Anticancer Drugs 1940s – 2010 by Source
Figure 9
Figure 9. All Anticancer Drugs 1940s – 2010 by Year/Source

Similar articles

See all similar articles

Cited by 940 PubMed Central articles

See all "Cited by" articles

Substances

LinkOut - more resources

Feedback